Cytokinetics Inc
aficamten
obstructive hypertrophic cardiomyopathy
Resolved
8days ago
FDA decision Β· Nov 14, 2026
What's at stake
The FDA's approval decision on aficamten for obstructive hypertrophic cardiomyopathy is due Nov 14, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
Β· SEC 8-K
verified 5mo ago
βThe Supplemental New Drug Application for MAPLE-HCM was accepted for filing by the U.S. Food and Drug Administration (FDA) with a PDUFA date of November 14, 2026.β